Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI>=3) Diffuse Large B-Cell Lymphoma

NCT03283202 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03283202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI>=3) Diffuse Large B-Cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
October 4, 2017
Completion date
December 16, 2020
Enrollment
35 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse b-cell lymphoma